DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2023 earnings per share estimates for shares of DICE Therapeutics in a research report issued on Thursday, March 16th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.57) for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for DICE Therapeutics’ current full-year earnings is ($2.83) per share. HC Wainwright also issued estimates for DICE Therapeutics’ Q3 2023 earnings at ($0.70) EPS and Q4 2023 earnings at ($0.76) EPS.
DICE has been the subject of a number of other research reports. Cowen initiated coverage on DICE Therapeutics in a research report on Wednesday, March 1st. They set an “outperform” rating for the company. TD Cowen assumed coverage on DICE Therapeutics in a report on Wednesday, March 1st. They set an “outperform” rating for the company. Finally, Cowen assumed coverage on DICE Therapeutics in a research report on Wednesday, March 1st. They set an “outperform” rating for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $65.86.
DICE Therapeutics Price Performance
Hedge Funds Weigh In On DICE Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System acquired a new stake in DICE Therapeutics in the 2nd quarter valued at approximately $219,000. VR Adviser LLC bought a new stake in shares of DICE Therapeutics in the 3rd quarter valued at about $15,514,000. DAFNA Capital Management LLC lifted its stake in DICE Therapeutics by 66.9% in the 2nd quarter. DAFNA Capital Management LLC now owns 156,904 shares of the company’s stock valued at $2,435,000 after purchasing an additional 62,904 shares during the last quarter. Barclays PLC grew its holdings in DICE Therapeutics by 318.0% during the third quarter. Barclays PLC now owns 5,956 shares of the company’s stock worth $120,000 after purchasing an additional 4,531 shares during the period. Finally, Driehaus Capital Management LLC increased its position in DICE Therapeutics by 5.0% during the second quarter. Driehaus Capital Management LLC now owns 2,230,538 shares of the company’s stock worth $34,618,000 after buying an additional 105,310 shares during the last quarter. Institutional investors own 91.51% of the company’s stock.
DICE Therapeutics Company Profile
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.